Repository logo

Browsing by Author "Wahn, U"

Now showing 1 - 3 of 3
  • ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
    Publication . Bousquet, J; Hellings, PW; Agache, I; Bedbrook, A; Bachert, C; Bergmann, KC; Bewick, M; Bindslev-Jensen, C; Bosnic-Anticevitch, S; Bucca, C; Caimmi, DP; Camargos, PAM; Canonica, G W; Casale, T; Chavannes, NH; Cruz, AA; De Carlo, G; Dahl, R; Demoly, P; Devillier, P; Fonseca, J; Fokkens, WJ; Guldemond, NA; Haahtela, T; Illario, M; Just, J; Keil, T; Klimek, L; Kuna, P; Larenas-Linnemann, D; Morais-Almeida, M; Mullol, J; Murray, R; Naclerio, R; O'Hehir, RE; Papadopoulos, NG; Pawankar, R; Potter, P; Ryan, D; Samolinski, B; Schunemann, HJ; Sheikh, A; Simons, FER; Stellato, C; Todo-Bom, A; Tomazic, PV; Valiulis, A; Valovirta, E; Ventura, MT; Wickman, M; Young, I; Yorgancioglu, A; Zuberbier, T; Aberer, W; Akdis, CA; Akdis, M; Annesi-Maesano, I; Ankri, J; Ansotegui, IJ; Anto, JM; Arnavielhe, S; Asarnoj, A; Arshad, H; Avolio, F; Baiardini, I; Barbara, C; Barbagallo, M; Bateman, D; Beghé, B; Bel, EH; Bennoor, KS; Benson, M; Białoszewski, AZ; Bieber, T; Bjermer, L; Blain, H; Blasi, F; Boner, L; Bonini, M; Bonini, S; Bosse, I; Bouchard, J; Boulet, LP; Bourret, R; Bousquet, PJ; Braido, F; Briggs, AH; Brightling, CE; Brozek, J; Buhl, R; Bunu, C; Burte, E; Bush, A; Caballero-Fonseca, F; Calderon, MA; Camuzat, T; Cardona, V; Carreiro-Martins, P; Carriazo, AM; Carlsen, K H; Carr, W; Cepeda Sarabia, AM; Cesari, M; Chatzi, L; Chiron, R; Chivato, T; Chkhartishvili, E; Chuchalin, AG; Chung, KF; Ciprandi, G; Correia de Sousa, J; Cox, L; Crooks, G; Custovic, A; Dahlen, SE; Darsow, U; Dedeu, T; Deleanu, D; Denburg, JA; De Vries, G; Didier, A; Dinh-Xuan, AT; Dokic, D; Douagui, H; Dray, G; Dubakiene, R; Durham, SR; Du Toit, G; Dykewicz, MS; Eklund, P; El-Gamal, Y; Ellers, E; Emuzyte, R; Farrell, J; Fink Wagner, A; Fiocchi, A; Fletcher, M; Forastiere, F; Gaga, M; Gamkrelidze, A; Gemicioğlu, B; Gereda, J E; van Wick, RG; González Diaz, S; Grisle, I; Grouse, L; Gutter, Z; Guzmán, MA; Hellquist-Dahl, B; Heinrich, J; Horak, F; Hourihane, JOB; Humbert, M; Hyland, M; Iaccarino, G; Jares, EJ; Jeandel, C; Johnston, SL; Joos, G; Jonquet, O; Jung, KS; Jutel, M; Kaidashev, I; Khaitov, M; Kalayci, O; Kalyoncu, A F; Kardas, P; Keith, PK; Kerkhof, M; Kerstjens, HAM; Khaltaev, N; Kogevinas, M; Kolek, V; Koppelman, GH; Kowalski, ML; Kuitunen, M; Kull, I; Kvedariene, V; Lambrecht, B; Lau, S; Laune, D; Le, LTT; Lieberman, P; Lipworth, B; Li, J; Lodrup Carlsen, KC; Louis, R; Lupinek, C; MacNee, W; Magar, Y; Magnan, A; Mahboub, B; Maier, D; Majer, I; Malva, J; Manning, P; De Manuel Keenoy, E; Marshall, GD; Masjedi, MR; Mathieu-Dupas, E; Maurer, M; Mavale-Manuel, S; Melén, E; Melo-Gomes, E; Meltzer, EO; Mercier, J; Merk, H; Miculinic, N; Mihaltan, F; Milenkovic, B; Millot-Keurinck, J; Mohammad, Y; Momas, I; Mösges, R; Muraro, A; Namazova-Baranova, L; Nadif, R; Neffen, H; Nekam, K; Nieto, A; Niggemann, B; Nogueira-Silva, L; Nogues, M; Nyembue, TD; Ohta, K; Okamoto, Y; Okubo, K; Olive-Elias, M; Ouedraogo, S; Paggiaro, P; Pali-Schöll, I; Palkonen, S; Panzner, P; Papi, A; Park, HS; Passalacqua, G; Pedersen, S; Pereira, AM; Pfaar, O; Picard, R; Pigearias, B; Pin, I; Plavec, D; Pohl, W; Popov, TA; Portejoie, F; Postma, D; Poulsen, LK; Price, D; Rabe, KF; Raciborski, F; Roberts, G; Robalo-Cordeiro, C; Rodenas, F; Rodriguez-Mañas, L; Rolland, C; Roman Rodriguez, M; Romano, A; Rosado-Pinto, J; Rosario, N; Rottem, M; Sanchez-Borges, M; Sastre-Dominguez, J; Scadding, GK; Scichilone, N; Schmid-Grendelmeier, P; Serrano, E; Shields, M; Siroux, V; Sisul, JC; Skrindo, I; Smit, HA; Solé, D; Sooronbaev, T; Spranger, O; Stelmach, R; Sterk, PJ; Strandberg, T; Sunyer, J; Thijs, C; Triggiani, M; Valenta, R; Valero, A; van Eerd, M; van Ganse, E; van Hague, M; Vandenplas, O; Varona, LL; Vellas, B; Vezzani, G; Vazankari, T; Viegi, G; Vontetsianos, T; Wagenmann, M; Walker, S; Wang, DY; Wahn, U; Werfel, T; Whalley, B; Williams, DM; Williams, S; Wilson, N; Wright, J; Yawn, BP; Yiallouros, PK; Yusuf, OM; Zaidi, A; Zar, HJ; Zernotti, ME; Zhang, L; Zhong, N; Zidarn, M
    The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
    2016Journal article Open access Show more
  • Fexofenadine is Efficacious and Safe in Children (Aged 6-11 Years) with Seasonal Allergic Rhinitis
    Publication . Rosado-Pinto, J; Wahn, U; Meltzer, E; Finn, A; Kowalski, M; Decosta, P; Hedlin, G; Scheinmann, P; Bachert, C; Baena-Cagnani, C; Potter, P; Simons, F; Ruuth, E
    Background: This is the first prospective, randomized, doubleblind, placebo-controlled study showing statistical improvement of an H1-antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period. Objective: This randomized, placebo-controlled, parallelgroup,double-blind study was performed to assess the efficacy and safety of fexofenadine in children with seasonal allergic rhinitis. Methods: This study was conducted at 148 centers in 15 countries. Nine hundred thirty-five children (aged 6-11 years) were randomized and treated with either fexofenadine HCl 30 mg (n = 464) or placebo (n = 471) tablets twice a day for 14 days. Individual symptoms (sneezing; rhinorrhea; itchy nose, mouth, throat, and/or ears; itchy, watery, and/or red eyes; and nasal congestion) were assessed at baseline and then daily at 7:00 AM and 7:00 PM (±1 hour) during the double-blind treatment period. Each total symptom score was the sum of all symptoms, excluding nasal congestion. The primary efficacy variable was the change from baseline in the average of the daily 12-hour evening reflective total symptom scores throughout the double-blind treatment. Safety was evaluated from adverse-event reporting, vital signs, physical examinations, and clinical laboratory data at screening and study end point.
    2003Journal article Open access Show more
  • Safety and Efficacy of Oral Fexofenadine in Children with Seasonal Allergic Rhinitis - a Pooled Analysis of Three Studies
    Publication . Meltzer, E; Scheinmann, P; Rosado-Pinto, J; Bachert, C; Hedlin, G; Wahn, U; Finn, A; Ruuth, E
    Allergic rhinitis is one of the most common clinical conditions in children; however, data regarding the safety of antihistamines in children with seasonal allergic rhinitis are limiting. To evaluate the safety and efficacy of fexofenadine in children with seasonal allergic rhinitis, data were pooled from three, double-blind, randomized, placebo-controlled, parallel-group, 2-week trials in children (6-11 year) with seasonal allergic rhinitis. All studies assessed fexofenadine HCl 30 mg b.i.d.; two studies included fexofenadine HCl at 15 and 60 mg b.i.d. Patients (and investigators) reported any adverse events during the trial. Physical examinations, including measurements of vital signs and laboratory tests, were performed. Efficacy assessments (total symptom score and individual symptom scores) were evaluated. Exposure to fexofenadine HCl 30 mg b.i.d. and to any fexofenadine dose exceeded 10,000 and 17,000 patient days, respectively. Incidences of adverse events, and discontinuations because of adverse events, were low and similar across treatment groups. In the placebo group, 24.4% of subjects reported adverse events compared with 24.1% for fexofenadine HCl 30 mg b.i.d., and 28.4% for all fexofenadine-treated groups. The most common adverse event overall was headache (4.3% placebo; 5.8% fexofenadine HCl 30 mg b.i.d.; and 7.2% any fexofenadine doses). Treatment-related adverse events were similar across treatment groups with no sedative effects. Fexofenadine HCl 30 mg b.i.d. was significantly superior to placebo in reducing the total symptom score and all individual seasonal allergic rhinitis symptoms, including nasal congestion (p < 0.05). Fexofenadine, at doses of up to 60 mg b.i.d., is safe and non-sedating, and fexofenadine HCl 30 mg b.i.d. effectively reduces all seasonal allergic rhinitis symptoms in children aged 6-11 years.
    2004-06Journal article Open access Show more